Article Text

Download PDFPDF
Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlAbstract/FREE Full Text

Q How do second generation antipsychotics compare with haloperidol for the treatment of acute schizophrenia?


Embedded ImageDesign:

Randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Unblinded (treating physician and participant aware of the treatment). Assessors of the Brief Psychiatric Rating Scale and side effects were blinded; the unblinded treating physician made the decision about discharge.

Embedded ImageFollow-up period

At least 3 weeks.

Embedded ImageSetting:

Six hospital adult psychiatric inpatient units, USA; recruitment January 2004 to February 2005.

Embedded ImagePatients:

327 newly admitted adult inpatients (aged 18 years and over) with DSM-IV schizophrenia, schizoaffective disorder or schizophreniform disorder. Exclusions: substance-induced psychotic disorder, bipolar disorder, major depressive disorder, history of non-response to study drugs or response to non-study drugs, pregnancy or breastfeeding, or medical condition contraindicating study treatments.

Embedded ImageIntervention:

Aripiprazole, haloperidol, …

View Full Text


  • For correspondence: Dr Robert E McCue, Department of Psychiatry, Woodhull Medical and Mental Health Center, 760 Broadway, Brooklyn, New York, USA; mccuer{at}

  • Sources of funding: Not stated.


  • Competing interests: Professor Taylor has received research funding and consultancy fees from all manufacturers of currently marketed second generation antipsychotics.